Shifting supply chains in an uncertain policy landscape

Although the initial upheaval from the Trump administration’s spring tariff announcements have somewhat settled, the global environment around trade is still uncertain. Pharma companies are paying close attention. How are companies rethinking their supply chains to retain some stability in the face of changing policy? What will come of pledges to expand US manufacturing? Join us to discuss the shifting landscape.

sponsored by

Key factors, critical insights, and essential expertise for selecting a cartridge-based drug delivery device

In recent years, the demand for more efficient and patient-friendly methods of medication delivery has increased significantly. What challenges are involved in developing proprietary devices, and how can deeper understanding of the infrastructure impact decision making? Join us as we explore the critical considerations in the development of drug delivery devices, with a specific focus on autoinjectors. We'll discuss the factors behind container selection, including manufacturing capabilities, nuances of filling, and design verification.

sponsored by

What happened to pharma 4.0?

Pharma 4.0 promised a digital revolution in biopharma manufacturing through IoT, automation, and big data. However, the term has largely faded from use in the C-level boardroom, overtaken by the rapid rise of artificial intelligence as the focal point for innovation. Is Pharma 4.0 obsolete, or is AI its catalyst for redefining the future of biopharma manufacturing? Our panelists will share insights directly from their C-level experiences on how to cut through the AI hype and industrialize AI for success in Good Manufacturing Practice environments.

sponsored by

In conversation with USP’s Ronald Piervincenzi

Branded drugs aren’t the only products vulnerable to the uncertainty pharmaceutical policy landscape — generics are under pressure, too. Hear from U.S. Pharmacopeia CEO Ronald Piervincenzi about how the industry is preparing for disruption, the importance of reliable supply chains, and the role U.S. regulators and policymakers have in maintaining safety and quality.

sponsored by

Battling wildfires in pharma supply chains: CDMO leaders weigh in

The pharma manufacturing chain is being upended by geopolitical uncertainties, changing regulations and manufacturing challenges - reducing the security and predictability that pharma needs to supply patients reliably. How can the industry better partner with CDMOs to rethink supply chains of the future and to ensure more predictable cost-efficiency and access globally? Senior Executive CDMO will discuss manufacturing solutions, building new capabilities and working in new ways to enable Global/Regional supply that's flexible, resilient and bespoke for the complex and highly varied pipelines. 

The Small Molecule Section panel spans: 

• Curia, the global leader in comprehensive API technology and manufacturing.
• Adare, with its unrivaled complex oral development and manufacturing expertise across US and in Europe.
• Big new Bend Bioscience with scaled-up development and manufacturing capabilities in the US.
• Oregon Freeze Dry, with an innovative oral manufacturing process expanding opportunities for pharma innovators.

sponsored by

sponsored by

Battling wildfires in biopharma supply chains: CDMO leaders weigh in

The Biologics Section includes executives from:

• FUJIFILM Biotechnologies which offers fully-integrated manufacturing centers of excellence in Europe, the US and Japan.
• Enzene with a unique high-yield, cost-efficient continuous biomanufacturing platform in the US and India.
• Bionova Scientific, a specialist in the development and manufacture of complex biologics and plasmid DNA based in the Bay Area.

sponsored by

sponsored by